Bosnian drug maker Bosnalijek's 2023 net profit down 17% y/y

The company's total revenue decreased 7.3% on the year to 187.3 million marka last year, while total expenses went down 5% to 175.2 million marka, Bosnalijek said in a bourse filing on Friday.

The company's shares last traded on the SASE on Friday, closing 2.56% higher at 20 marka.

Bosnalijek is the largest pharmaceuticals company in Bosnia and Herzegovina.

(1 euro = 1.956 marka)